MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

ADMA Biologics Inc

Затворен

СекторЗдравеопазване

19.4 -4.1

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

19.16

Максимум

20.22

Ключови измерители

By Trading Economics

Приходи

76M

112M

Продажби

-2.3M

118M

P/E

Средно за сектора

23.975

63.778

EPS

0.136

Марж на печалбата

95.191

Служители

685

EBITDA

-2.7M

40M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+28.73% upside

Дивиденти

By Dow Jones

Следващи печалби

8.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

797M

4.6B

Предишно отваряне

23.5

Предишно затваряне

19.4

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

ADMA Biologics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.04.2025 г., 23:04 ч. UTC

Топ новини

JPMorgan Raises Risk of U.S., Global Recession to 60%

3.04.2025 г., 22:40 ч. UTC

Значими двигатели на пазара

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3.04.2025 г., 22:18 ч. UTC

Придобивния, сливания и поглъщания

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3.04.2025 г., 18:51 ч. UTC

Придобивния, сливания и поглъщания

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3.04.2025 г., 23:43 ч. UTC

Пазарно говорене

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3.04.2025 г., 23:41 ч. UTC

Пазарно говорене

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3.04.2025 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3.04.2025 г., 22:21 ч. UTC

Придобивния, сливания и поглъщания

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3.04.2025 г., 21:43 ч. UTC

Топ новини
Печалби

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3.04.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

3.04.2025 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

3.04.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

3.04.2025 г., 20:43 ч. UTC

Пазарно говорене

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3.04.2025 г., 20:34 ч. UTC

Топ новини

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3.04.2025 г., 20:23 ч. UTC

Топ новини

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3.04.2025 г., 20:15 ч. UTC

Придобивния, сливания и поглъщания

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3.04.2025 г., 19:55 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

3.04.2025 г., 19:55 ч. UTC

Пазарно говорене

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3.04.2025 г., 19:21 ч. UTC

Пазарно говорене

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3.04.2025 г., 19:15 ч. UTC

Пазарно говорене

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3.04.2025 г., 18:45 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

3.04.2025 г., 18:45 ч. UTC

Пазарно говорене

Gold Drops In Tariff Fallout -- Market Talk

3.04.2025 г., 18:39 ч. UTC

Пазарно говорене

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3.04.2025 г., 18:38 ч. UTC

Топ новини

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3.04.2025 г., 18:30 ч. UTC

Топ новини

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3.04.2025 г., 18:20 ч. UTC

Пазарно говорене

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3.04.2025 г., 18:18 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

3.04.2025 г., 18:17 ч. UTC

Пазарно говорене

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3.04.2025 г., 18:04 ч. UTC

Пазарно говорене

US Sees More Job Openings in Construction, Transportation -- Market Talk

3.04.2025 г., 17:55 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

ADMA Biologics Inc Прогноза

Ценова цел

By TipRanks

28.73% нагоре

12-месечна прогноза

Среден 25 USD  28.73%

Висок 25 USD

Нисък 25 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за ADMA Biologics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

2

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

19.8 / 20.29Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.